Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Abstract Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Antonio Martin-Bastida, Roberta J. Ward, Rexford Newbould, Paola Piccini, David Sharp, Christina Kabba, Maneesh C. Patel, Michael Spino, John Connelly, Fernando Tricta, Robert R. Crichton, David T. Dexter
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/447847d27a3f44eea2861e4c6d11074c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/447847d27a3f44eea2861e4c6d11074c

Ejemplares similares